AHRR methylation in heavy smokers: associations with smoking, lung cancer risk, and lung cancer mortality

BMC Cancer

Table 4 Mortality^a by cg05575921 percent methylation for all lung cancer cases and by histotype

	All lung cancer cases^b			Adenocarcinoma			Squamous cell carcinoma			Small cell
cg05575921 methylation %	Deaths	Total	HR (95% CI)	Deaths	Total	HR (95% CI)	Deaths	Total	HR (95% CI)	Deaths	Total	HR (95% CI)
Lung cancer-specific mortality
Continuous 10% decrease	313	372	1.08 (0.98, 1.19)	117	148	1.21 (1.03, 1.43)	94	115	0.98 (0.82, 1.17)	77	81	1.20 (0.93, 1.54)
Q1 (highest; hyper-methylated)	59	74	Ref	23	31	Ref	15	19	Ref	16	19	Ref
Q2	61	74	0.93 (0.64, 1.36)	26	35	1.11 (0.58, 2.11)	20	23	1.02 (0.48, 2.14)	12	13	1.01 (0.37, 2.70)
Q3	63	75	1.12 (0.75, 1.67)	21	28	1.09 (0.54, 2.19)	12	17	0.89 (0.39, 2.03)	24	24	1.79 (0.79, 4.02)
Q4	65	74	1.13 (0.75, 1.71)	23	27	1.97 (0.95, 4.10)	23	27	0.86 (0.39, 1.92)	14	14	1.01 (0.35, 2.88)
Q5 (lowest; hypo-methylated)	65	75	1.46 (0.95, 2.22)	24	27	2.32 (1.12, 4.82)	24	29	1.07 (0.49, 2.36)	11	11	3.68 (1.32, 10.25)
	P-trend		0.05	P-trend		0.01	P-trend		1.00	P-trend		0.04
All-cause mortality
Continuous 10% decrease	357	372	1.07 (0.97, 1.17)	137	148	1.21 (1.03, 1.41)	113	115	0.97 (0.82, 1.14)	80	81	1.14 (0.89, 1.47)
Q1 (highest; hyper-methylated)	73	74	Ref	30	31	Ref	19	19	Ref	19	19	Ref
Q2	69	74	0.87 (0.61, 1.24)	31	35	1.05 (0.58, 1.89)	23	23	1.10 (0.56, 2.20)	12	13	0.82 (0.31, 2.18)
Q3	71	75	1.07 (0.74, 1.56)	24	28	1.08 (0.56, 2.11)	17	17	1.11 (0.53, 2.31)	24	24	1.45 (0.66, 3.17)
Q4	70	74	1.01 (0.68, 1.49)	25	27	1.65 (0.83, 3.29)	26	27	0.78 (0.36, 1.66)	14	14	0.83 (0.30, 2.28)
Q5 (lowest; hypo-methylated)	74	75	1.42 (0.96, 2.10)	27	27	2.37 (1.20, 4.71)	28	29	1.04 (0.50, 2.17)	11	11	2.95 (1.09, 7.96)
	P-trend		0.06	P-trend		0.01	P-trend		0.76	P-trend		0.09

Abbreviations: CI confidence Interval, NSCLC non-small cell lung cancer, NSCLC, NOS non-small cell lung cancer, not otherwise specified, HR hazard ratio
^aCox proportional hazards model results adjusted for age at blood draw, sex, years between blood draw and lung cancer diagnosis, and years since quit smoking at blood draw. All models include early, late, or unknown stage as a strata variable
^b “All lung cancer cases” includes adenocarcinoma, squamous cell carcinoma, and small cell cases as well as not otherwise specified non-small cell lung cancer (NSCLC, NOS; n = 16) and unknown/no pathology (n = 12)

ISSN: 1471-2407